within Pharmacolibrary.Drugs.ATC.A;

model A10BG03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.83,
    Cl             = 3.43 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.0254,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005833333333333334,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Pioglitazone is a thiazolidinedione antidiabetic drug used to improve glycemic control in adults with type 2 diabetes mellitus either as monotherapy or in combination with other antidiabetic agents. It acts as an agonist at peroxisome proliferator-activated receptor gamma (PPAR-γ), reducing insulin resistance. Pioglitazone is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single oral dose administration.</p><h4>References</h4><ol><li><p>Wearn, JM, et al., &amp; McCutcheon, LJ (2011). Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. <i>Journal of veterinary pharmacology and therapeutics</i> 34(3) 252–258. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.2010.01217.x&quot;>10.1111/j.1365-2885.2010.01217.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21492190/&quot;>https://pubmed.ncbi.nlm.nih.gov/21492190</a></p></li><li><p>Al-Majed, A, et al., &amp; Al-Jenoobi, FI (2016). Pioglitazone. <i>Profiles of drug substances, excipients, and related methodology</i> 41 379–438. DOI:<a href=&quot;https://doi.org/10.1016/bs.podrm.2015.11.002&quot;>10.1016/bs.podrm.2015.11.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26940171/&quot;>https://pubmed.ncbi.nlm.nih.gov/26940171</a></p></li><li><p>Choi, JS, et al., &amp; Choi, DH (2016). Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. <i>European journal of drug metabolism and pharmacokinetics</i> 41(3) 231–238. DOI:<a href=&quot;https://doi.org/10.1007/s13318-014-0249-y&quot;>10.1007/s13318-014-0249-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25549928/&quot;>https://pubmed.ncbi.nlm.nih.gov/25549928</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BG03;
